SCHEMBL3818879

SCHEMBL3818879

CN(C)CC1=C(c2cccnc2)c2ccccc2OC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2D6 P10635 2/20 0.45
MAOB P27338 2/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
KDM4E B2RXH2 3/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
ATM Q13315 1/20 0.40
CYP11B1 P15538 4/20 0.39
CYP11B2 P19099 4/20 0.39
CYP19A1 P11511 3/20 0.39
ROCK2 O75116 1/20 0.39
CYP17A1 P05093 1/20 0.39
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3820831 0.89 CYP2A6 (0.44) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
SCHEMBL3823962 0.81 CHRM1 (0.50) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
SCHEMBL3819127 0.81 CYP11B1 (0.53) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL5456114 0.80 CHRM1 (0.49) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
SCHEMBL3821113 0.79 CYP11B1 (0.48) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
SCHEMBL7610280 0.78 PTGS2 (0.37) CYP2D6KDM4EGAACHRM2CHRM4
Hydrochloric Acid SCHEMBL5457486 0.78 CYP11B1 (0.47) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL8018678 0.77 ALDH1A1 (0.38) CYP2D6MAOBKDM4EGAACHRM2
SCHEMBL7605957 0.76 ESR1 (0.52) MAOBKDM4EGAACYP19A1ALDH1A1
SCHEMBL3823892 0.75 CYP2A6 (0.45) CYP2A6CYP2C19CYP2D6CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758860-B1 SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES GRUENENTHAL GMBH (DE) 2009-09-02 EP claimed
US-20070203192-A1 Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety GRUENENTHAL GMBH 2007-08-30 US claimed
US-8278338-B2 Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety GRUENENTHAL GMBH (DE) 2012-10-02 US disclosed
EP-2097416-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen, Inc (US) 2009-09-09 EP disclosed
EP-1758860-B1 SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES GRUENENTHAL GMBH (DE) 2009-09-02 EP disclosed
WO-2008076425-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed
US-20070203192-A1 Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety GRUENENTHAL GMBH 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203192-A1 Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety OPRK1, OPRM1, OPRL1 CYP2A6 296/4885CYP2C19 108/4885CYP2D6 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.